Meda Pharmaceuticals Inc. Sustainability Profile
Meda Pharmaceuticals Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across various regions. Founded in 1999, the company has established itself as a leader in the development and distribution of specialty pharmaceuticals, particularly in the fields of respiratory, pain management, and dermatology. Meda's core offerings include a range of innovative prescription medications and over-the-counter products, distinguished by their commitment to quality and patient care. The company has achieved significant milestones, including strategic partnerships and a robust portfolio that enhances its market position. With a focus on improving patient outcomes, Meda Pharmaceuticals continues to make strides in the healthcare sector, solidifying its reputation as a trusted name in pharmaceuticals.
DitchCarbon Score
How does Meda Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Meda Pharmaceuticals Inc.'s score of 45 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Meda Pharmaceuticals Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Viatris Inc., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or specific climate pledges from Meda Pharmaceuticals Inc., it is important to note that any climate initiatives or targets would likely be aligned with those set by its parent company, Viatris Inc. This includes potential commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are cascaded from Viatris Inc. at a corporate family level. As a subsidiary, Meda Pharmaceuticals Inc. may benefit from Viatris Inc.'s broader sustainability strategies, although specific details regarding emissions reduction initiatives or targets are not available at this time. The absence of direct emissions data highlights the need for increased transparency and commitment to climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 302,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Meda Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is Meda Pharmaceuticals Inc.'s Location?
Meda Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Meda Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
